BioSpace

Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raft

Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with Ayrmid will go through.

By BioSpace

1 min read
Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raft
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights